CM
CRVS icon

Caption Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Caption Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.84M Buy
190,000
+30,000
+19% +$416K 0.01% 786
2026
Q1 		$2.34M Buy
160,000
+135,000
+540% +$2.15M 0.01% 779
2025
Q4 		$193K Buy
+25,000
New +$197K ﹤0.01% 1383
2025
Q2 		– Sell
-50,000
Closed -$159K – 1537
2025
Q1 		$159K Sell
50,000
-581,200
-92% -$2.74M ﹤0.01% 1306
2024
Q4 		$3.38M Buy
+631,200
New +$4.71M 0.03% 512

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caption Management's CRVS Position: Q2 2026 in Review

Caption Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 64,034 shares worth $957K. The stake represents ﹤0.01% of the portfolio and ranks #1149 among its holdings. This is a return to the name: Caption Management previously reported a position in CRVS as recently as Q4 2025.

Caption Management first reported a position in CRVS in Q2 2025 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Caption Management held 64,034 shares of Corvus Pharmaceuticals worth $957K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Caption Management position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1149 holding.
  • Caption Management first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.